| Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy J Montero, KA Sarosiek, JD DeAngelo, O Maertens, J Ryan, D Ercan, ... Cell 160 (5), 977-989, 2015 | 384 | 2015 |
| The public repository of xenografts enables discovery and randomized phase II-like trials in mice EC Townsend, MA Murakami, A Christodoulou, AL Christie, J Köster, ... Cancer cell 29 (4), 574-586, 2016 | 336 | 2016 |
| Why do BCL-2 inhibitors work and where should we use them in the clinic? J Montero, A Letai Cell Death & Differentiation 25 (1), 56-64, 2018 | 335 | 2018 |
| Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors D Ercan, C Xu, M Yanagita, CS Monast, CA Pratilas, J Montero, ... Cancer discovery 2 (10), 934-947, 2012 | 330 | 2012 |
| Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma J Montero, A Morales, L Llacuna, JM Lluis, O Terrones, G Basanez, ... Cancer research 68 (13), 5246-5256, 2008 | 289 | 2008 |
| BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response KA Sarosiek, X Chi, JA Bachman, JJ Sims, J Montero, L Patel, A Flanagan, ... Molecular cell 51 (6), 751-765, 2013 | 274 | 2013 |
| KPT‐330 inhibitor of CRM 1 (XPO 1)‐mediated nuclear export has selective anti‐leukaemic activity in preclinical models of T‐cell acute lymphoblastic leukaemia and acute myeloid … J Etchin, T Sanda, MR Mansour, A Kentsis, J Montero, BT Le, AL Christie, ... British journal of haematology 161 (1), 117-127, 2013 | 212 | 2013 |
| Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax J Montero, J Stephansky, T Cai, GK Griffin, L Cabal-Hierro, K Togami, ... Cancer discovery 7 (2), 156-164, 2017 | 206 | 2017 |
| Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis D Lagares, A Santos, PE Grasberger, F Liu, CK Probst, RA Rahimi, ... Science translational medicine 9 (420), eaal3765, 2017 | 197 | 2017 |
| p53 regulates a non-apoptotic death induced by ROS J Montero, C Dutta, D Van Bodegom, D Weinstock, A Letai Cell Death & Differentiation 20 (11), 1465-1474, 2013 | 152 | 2013 |
| Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death J Montero, M Mari, A Colell, A Morales, G Basañez, C Garcia-Ruiz, ... Biochimica et Biophysica Acta (BBA)-Bioenergetics 1797 (6-7), 1217-1224, 2010 | 139 | 2010 |
| iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry J Ryan, J Montero, J Rocco, A Letai Biological chemistry 397 (7), 671-678, 2016 | 135 | 2016 |
| Mitochondrial cholesterol in health and disease C Garcia-Ruiz, M Mari, A Colell Riera, A Morales, F Caballero, J Montero, ... Universidad de Murcia, 2009 | 130 | 2009 |
| Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia SC Wu, LS Li, N Kopp, J Montero, B Chapuy, A Yoda, AL Christie, H Liu, ... Cancer cell 28 (1), 29-41, 2015 | 118 | 2015 |
| Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice J Etchin, J Montero, A Berezovskaya, BT Le, A Kentsis, AL Christie, ... Leukemia 30 (1), 0-0, 2016 | 94 | 2016 |
| Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response DE Park, J Cheng, C Berrios, J Montero, M Cortés-Cros, S Ferretti, ... Proceedings of the National Academy of Sciences 116 (3), 1027-1032, 2019 | 93 | 2019 |
| The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading A Baulies, J Montero, N Matías, N Insausti, O Terrones, G Basañez, ... Redox biology 14, 164-177, 2018 | 67 | 2018 |
| CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity AC Watt, P Cejas, MJ DeCristo, O Metzger-Filho, EYN Lam, X Qiu, ... Nature Cancer 2 (1), 34-48, 2021 | 66 | 2021 |
| DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance K Togami, T Pastika, J Stephansky, M Ghandi, AL Christie, KL Jones, ... The Journal of clinical investigation 129 (11), 5005-5019, 2019 | 65 | 2019 |
| Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies J Montero, C Gstalder, DJ Kim, D Sadowicz, W Miles, M Manos, ... Nature communications 10 (1), 5157, 2019 | 57 | 2019 |
